Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | GRN | P28799 | 3/20 | 0.56 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.56 |
| ▸ | F10 | P00742 | 4/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031357 | 1.00 | ALDH1A1 (0.59) | ALDH1A1GRNSORT1F10CA2 | |
| SCHEMBL4030871 | 0.86 | TAS1R3 (0.59) | ALDH1A1F10 | |
| SCHEMBL4466138 | 0.84 | CA2 (0.49) | ALDH1A1F10CA2CA1SMN1; SMN2 | |
| SCHEMBL4028934 | 0.84 | CA2 (0.49) | ALDH1A1F10CA2CA1SMN1; SMN2 | |
| SCHEMBL3425960 | 0.80 | SMN1; SMN2 (0.52) | ALDH1A1F10CA2CA1LMNA | |
| SCHEMBL3425969 | 0.80 | SMN1; SMN2 (0.52) | ALDH1A1F10CA2CA1LMNA | |
| SCHEMBL21612138 | 0.79 | GRN (0.58) | ALDH1A1GRNSORT1CA2CA1 | |
| SCHEMBL21612139 | 0.79 | GRN (0.58) | ALDH1A1GRNSORT1CA2CA1 | |
| SCHEMBL13754450 | 0.78 | SMN1; SMN2 (0.59) | ALDH1A1LMNASMN1; SMN2MAPK1 | |
| SCHEMBL27706200 | 0.78 | SMN1; SMN2 (0.46) | ALDH1A1F10LMNASMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579346-B2 | (R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]4-methylvaleramide, for example; inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors | MERCK PATENT GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-20060052376-A1 | Carboxamides | MERCK PATENT GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052376-A1 | Carboxamides | F11, F12, F10 | ALDH1A1 2592/4885GRN 2895/4885SORT1 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.